Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NINA-1: Intranasal vs Intramuscular Naloxone for Opioid Overdose
NCT03518021Phase 3Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- May 2018
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naloxone in opioid overdose, sponsored by Norwegian University of Science and Technology. Primary endpoint: Return of spontaneous respiration at 10 months. Started May 2018; status: completed.
02
Drugs
naloxone
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT03518021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03518021.